Vir Biotechnology, Inc. (VIR) Operating Margin
- Operating margin · 12 months: Value -92.40%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -92.40% | Operating income / revenue. Period ending 2026-06-30. $-280.19M ÷ $303.23M × 100 ≈ -92.40% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -280.19M USD | Operating Income (Loss) |
| Revenue | 303.23M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 484.02M USD | Research and Development Expense |
| Selling, general and administration | 99.38M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-280.19M | $303.23M | (m) | $484.02M | $99.38M | -92.40% |
| 2026-03-31 | $-472.07M | $65.50M | (m) | $446.24M | $91.47M | -720.77% |
| 2025-12-31 | $-479.33M | $68.56M | (m) | $455.97M | $92.07M | -699.18% |
| 2025-09-30 | $-548.56M | $16.86M | (m) | $473.70M | $95.16M | -3253.60% |
| 2025-06-30 | $-606.42M | $19.00M | (m) | $517.41M | $98.67M | -3191.67% |
| 2025-03-31 | $-646.63M | $20.86M | (m) | $525.02M | $106.65M | -3099.71% |
| 2024-12-31 | $-587.16M | $74.20M | (m) | $506.50M | $119.03M | -791.27% |
| 2024-09-30 | $-609.03M | $78.62M | (m) | $519.33M | $137.16M | -774.67% |
| 2024-06-30 | $-564.46M | $78.88M | (m) | $469.18M | $152.34M | -715.62% |
| 2024-03-31 | $-621.01M | $79.60M | (m) | $532.15M | $167.54M | -780.18% |
| 2023-12-31 | $-684.30M | $86.18M | (m) | $589.67M | $178.05M | -794.04% |
| 2023-09-30 | $-695.79M | $118.80M | (m) | $632.93M | $173.70M | -585.67% |
| 2023-06-30 | $-314.10M | $490.72M | (m) | $598.84M | $175.80M | -64.01% |
| 2023-03-31 | $-324.13M | $446.30M | (m) | $542.06M | $170.28M | -72.63% |
| 2022-12-31 | $833.07M | $1.62B | (m) | $474.65M | $161.76M | 51.56% |
| 2022-09-30 | $1.56B | $2.38B | (m) | $447.82M | $178.80M | 65.37% |
| 2022-06-30 | $1.31B | $2.11B | (m) | $432.32M | $186.12M | 61.99% |
| 2022-03-31 | $1.59B | $2.33B | (m) | $403.36M | $173.31M | 68.50% |
| 2021-12-31 | $420.75M | $1.10B | (m) | $448.01M | $160.79M | 38.41% |
| 2021-09-30 | $-259.40M | $284.40M | (m) | $406.76M | (m) | -91.21% |
| 2021-06-30 | $-293.63M | $182.71M | (m) | $378.77M | (m) | -160.71% |
| 2021-03-31 | $-383.70M | $72.63M | (m) | $372.30M | (m) | -528.33% |
| 2020-12-31 | $-296.98M | $76.37M | (m) | $302.41M | (m) | -388.88% |
| 2020-09-30 | $-252.34M | $75.61M | (m) | $268.25M | (m) | -333.71% |
| 2020-06-30 | $-212.40M | $75.09M | (m) | $237.43M | (m) | -282.87% |
| 2020-03-31 | $-219.12M | $10.15M | (m) | $187.58M | (m) | -2159.23% |
| 2019-12-31 | $-177.98M | $8.09M | (m) | $148.47M | (m) | -2199.72% |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $11.72M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $11.90M | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-118.69M | $10.67M | (m) | $100.23M | (m) | -1112.60% |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-81.50M | $2.71M | (m) | $62.51M | (m) | -3009.49% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |